首页> 美国卫生研究院文献>Frontiers in Neurology >PKG Movement Recording System Use Shows Promise in Routine Clinical Care of Patients With Parkinsons Disease
【2h】

PKG Movement Recording System Use Shows Promise in Routine Clinical Care of Patients With Parkinsons Disease

机译:PKG运动记录系统的使用在帕金森氏病患者的常规临床护理中显示出良好的前景

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Parkinson's disease (PD) is a debilitating, neurodegenerative disorder that affects nearly one million people. It's hallmark signs and symptoms include slow movements, rigidity, tremor, and unstable posture. Additionally, non-motor symptoms such as sleeplessness, depression, cognitive impairment, impulse control behaviors (ICB) have been reported. Today, treatment regimens to modify disease progression do not exist and as such, treatment is focused on symptom relief. Additionally, physicians are challenged to base their diagnoses and treatment plans on unreliable self-reported symptoms, even when used in conjunction to validated assessments such as the Unified Parkinson's Disease Rating Scale (UPDRS) and clinical exams. Wearable technology may provide clinicians objective measures of motor problems to supplement current subjective methods. Global Kinetics Corporation (GKC) has developed a watch-device called the Personal KinetiGraph (PKG) that records movements and provides patients medication dosing reminders. A separate clinician-use report supplies longitudinal motor and event data. The PKG was FDA-cleared in September 2016. We studied 63 PD patients during 85 routine care visits in 2 US academic institutions, evaluating the clinical utility of the PKG. Patients wore a PKG for 6 continuous days before their visit. Next, PKG data was uploaded to produce a report. In clinic, physicians discussed PD symptoms with patients and conducted a motor examination prior to reviewing the PKG report and comparing it to their initial assessments. Lastly, patient, caregiver and physician satisfaction surveys were conducted by each user. Across all visits when patients did not report bradykinesia or dyskinesia, the PKG reported these symptoms (50 and 33% of the time, respectively). The PKG provided insights for treatment plans in 50 (79%) patients across 71 (84%) visits. Physicians found improved patient dialogue in 50 (59%) visits, improved ability to assess treatment impact in 32 (38%) visits, and improved motor assessment in 28 (33%) visits. Patients stated in 82% of responses that they agreed or strongly agreed in PKG training, usability, performance, and satisfaction. In 39% of responses, they also reported a very valuable impact on their care. PKG use in 63 PD patients within our clinical practice showed clinically relevant utility in many areas.
机译:帕金森氏病(PD)是一种令人衰弱的神经退行性疾病,影响了近100万人。它的标志性迹象和症状包括动作缓慢,僵硬,震颤和姿势不稳。另外,已经报告了非运动性症状,例如失眠,抑郁,认知障碍,冲动控制行为(ICB)。如今,不存在改变疾病进展的治疗方案,因此,治疗集中在症状缓解上。此外,即使将其与诸如帕金​​森病统一评分量表(UPDRS)和临床检查等经过验证的评估结合使用时,医生也要根据其不可靠的自我报告症状制定诊断和治疗计划。可穿戴技术可以为临床医生提供运动问题的客观测量方法,以补充当前的主观方法。 Global Kinetics Corporation(GKC)开发了一种称为个人KinetiGraph(PKG)的手表设备,该手表可以记录运动并向患者提供用药剂量提醒。单独的临床医生使用报告提供了纵向运动和事件数据。 PKG于2016年9月获得FDA批准。我们在2个美国学术机构的85次常规护理就诊期间对63名PD患者进行了研究,评估了PKG的临床效用。患者在就诊前连续6天佩戴PKG。接下来,将PKG数据上传以生成报告。在临床中,医生与患者讨论了PD症状并进行了运动检查,然后再检查PKG报告并将其与他们的初始评估进行比较。最后,由每个用户进行患者,护理人员和医师满意度调查。在所有未报告运动迟缓或运动障碍的访视中,PKG报告了这些症状(分别占50%和33%)。 PKG为71(84%)次就诊的50(79%)位患者提供了治疗计划见解。医师发现,在50(59%)次就诊中改善了患者对话,在32(38%)次就诊中改善了评估治疗效果的能力,在28(33%)次就诊中改善了运动评估。患者在82%的回应中表示他们在PKG训练,可用性,性能和满意度上同意或强烈同意。在39%的回复中,他们还报告了对其护理的非常宝贵的影响。在我们的临床实践中,对63名PD患者使用PKG在许多领域显示出与临床相关的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号